QbD Chair for Precision Oncology Research in Glioblastoma extended for three years
The QbD Chair supports the research of Professor Frederik De Smet on glioblastoma, an aggressive form of brain cancer. Behind the establishment of this chair lies a personal story.
Frederik De Smet, along with his two close friends, Bart Van Acker and Pieter Van Vlierberghe, studied bioengineering together. Bart founded the company QbD (Quality by Design), a consulting firm in life sciences. Frederik and Pieter became cancer researchers, one at KU Leuven and the other at UGent. Pieter specialized in pediatric leukemia and excelled in his field. A few years ago, he himself was diagnosed with an aggressive brain tumor, which proved fatal at the end of 2022. He was only 42 years old.
When Pieter received the diagnosis, he reached out to his former classmate Frederik, who was conducting research in his lab on better treatments for glioblastoma. Pieter and Frederik decided to collaborate and asked Bart Van Acker if he would financially support that research. And so, the ball started rolling. Unfortunately, Pieter did not benefit from the research himself, although he hoped that others after him would have better chances of recovery.
Frederik De Smet and his research team are working on making that hope a reality, supported by the QbD chair. After an initial three-year term, QbD decided to extend the chair for another three years. This extension was celebrated on January 11, 2024.
The extension of the chair is a blessing for the research, which is a long-term endeavor. Glioblastoma is one of the most challenging forms of cancer to treat, with a survival rate of less than five percent over five years, despite intensive standard therapy. The harsh reality is that almost all clinical trials in the past twenty years have failed, attributed to the wide variety of patients and the heterogeneous nature of each individual tumor. This is why the financial boost from this chair is so crucial, says Frederik De Smet:
“Patronage allows us to develop new ideas and think outside the box. We use it to hire a doctoral student who explores avenues for which we do not receive research funding elsewhere.” The data generated by his team serves as a lever to win larger project grants. De Smet adds, “With the research data from the first term, we recently secured a large European grant of 12 million euros. We want to build on that momentum to bring better treatments for glioblastoma within reach.”
Shoulder to shoulder, Bart Van Acker and Frederik De Smet continue the work, in memory of Pieter.
Find out all about patronage at KU Leuven and UZ Leuven here. Learn more about the QbD Chair here.
Related News
ArtiQ joins forces with Clario in strategic acquisition deal to transform respiratory solutions
Leuven models help unlock the dark part of space in the largest European Space Agency mission ever
Zeopore is making its mark in emerging green applications through catalyst optimization leadership
Leuven-based hydrogen panels become an official KU Leuven spin-off
Leuven's imec research centre targets 1950 new hires by 2035
Materialise plays crucial role in world's first-ever eye transplant
KU Leuven students win the world championships for solar cars!
Leuven-based VirusBank Platform enhances society's preparedness against future viral epidemics and pandemics
Leuven's Centre for Drug Design and Discovery (CD3) raises € 70.5 Million
International School in Leuven opens new school building for children of expats
Qaelum NV Partners with I-MED Radiology Network to Enhance Patient Dose Analysis and Incident Reporting in the ANZ Region
Leuven-based Axelera AI brings first products to a potential 30 billion dollar market
How can we help?
The Leuven MindGate team is at your disposal for any questions about the Leuven Innovation Region. Do you want to invest, work or study in the region? We can help you find your way.
We also facilitate collaboration and innovation between companies, knowledge institutes and government within the Leuven Innovation Region, and we are happy to guide any of these stakeholders towards innovation.